685 A first-in-human Phase 1/2 clinical trial of SIRPαlow activated macrophages (SIRPant-M) for the treatment of R/R-NHL

685 A first-in-human Phase 1/2 clinical trial of SIRPαlow activated macrophages (SIRPant-M) for the treatment of R/R-NHL

Bibliographic Details
Main Authors:	Koby Kidder, Rita N Barcia, Stephen Fogelson, Candida Fratazzi, Nathanael McCurley
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

S219: FIRST CLINICAL STUDY OF THE ANTI-SIGNAL REGULATORY PROTEIN-ALPHA (SIRPΑ) ANTIBODY CC-95251 COMBINED WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL)
by: P. Strati, et al.
Published: (2022-06-01)

A phase 1 first‐in‐human study of GS‐0189, an anti‐signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL)
by: Mayur Narkhede, et al.
Published: (2023-05-01)

Nicotine Suppresses Phagocytic Ability of Macrophages by Regulating the miR-296-3p–SIRPα Axis
by: Zhen Liu, et al.
Published: (2023-01-01)

CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPα1
by: Vernon-Wilson, E, et al.
Published: (2000)

<i>Leishmania</i> Infection-Induced Proteolytic Processing of SIRPα in Macrophages
by: Hana Hirai, et al.
Published: (2023-04-01)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
by: Liu Rui, et al.
Published: (2023-08-01)

Development of therapeutic antibodies against SIRPα
by: Chan, Lynn Xing Hui
Published: (2017)

Macrophage Biomarkers sCD163 and sSIRPα in Serum Predict Mortality in Sarcoma Patients
by: Ninna Aggerholm-Pedersen, et al.
Published: (2023-02-01)

Cancer Therapy Targeting CD47/SIRPα
by: Nazli Dizman, et al.
Published: (2021-12-01)

Membrane nanoclusters of FcγRI segregate from inhibitory SIRPα upon activation of human macrophages
by: Lopes, F, et al.
Published: (2017)

Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer
by: Alexandra Giatromanolaki, et al.
Published: (2022-04-01)

Modified exosomal SIRPα variants alleviate white matter injury after intracerebral hemorrhage via microglia/macrophages
by: Xinjie Gao, et al.
Published: (2022-11-01)

CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies
by: Jason C. Andrechak, et al.
Published: (2022-04-01)

Inspired by Kabuki: Reflections on a Theatrical Experiment with Wilde’s Salomé
by: Dallas McCurley
Published: (2010-12-01)

Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade
by: Abdullahi Alausa, et al.
Published: (2022-07-01)

SIRPα blockade improves the antitumor immunity of radiotherapy in colorectal cancer
by: Kai Ji, et al.
Published: (2023-06-01)

A New Serum Macrophage Checkpoint Biomarker for Innate Immunotherapy: Soluble Signal-Regulatory Protein Alpha (sSIRPα)
by: Yoanna V. Vladimirova, et al.
Published: (2022-07-01)

SIRPα maintains macrophage homeostasis by interacting with PTK2B kinase in Mycobacterium tuberculosis infection and through autophagy and necroptosis
by: Di Wang, et al.
Published: (2022-11-01)

Membrane-Mediated Cooperative Interactions of CD47 and SIRP<i>α</i>
by: Long Li, et al.
Published: (2023-11-01)

Falls from height : a guide to rescue planning /
by: McCurley, Loui, 1965-
Published: (2013)

6.685 Electric Machines, Fall 2003
by: Kirtley, James L.
Published: (2003)

6.685 Electric Machines, Fall 2005
by: Kirtley Jr., James L.
Published: (2005)

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells
by: Timo K van den Berg, et al.
Published: (2023-04-01)

Charmonium production in pNe collisions at $$\sqrt{s_{\scriptscriptstyle \text {NN}}} =68.5$$ s NN = 68.5 GeV
by: R. Aaij, et al.
Published: (2023-07-01)

Charmonium production in pNe collisions at $$\sqrt{s_{\scriptscriptstyle \text {NN}}} =68.5$$ s NN = 68.5 GeV
by: Aaij, R., et al.
Published: (2023)

RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages
by: Pedro Cabrales
Published: (2019-04-01)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
by: Pengcheng Zhao, et al.
Published: (2024-01-01)

Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
by: Xukai Luo MM, et al.
Published: (2023-02-01)

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
by: Renée Bouwstra, et al.
Published: (2022-08-01)

P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY
by: Stephen Spurgeon, et al.
Published: (2023-08-01)

650 Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer
by: Noam Harpaz, et al.
Published: (2023-11-01)

Comparative structural analyses of the NHL domains from the human E3 ligase TRIM–NHL family
by: Apirat Chaikuad, et al.
Published: (2022-11-01)

The SIRP family of receptors and immune regulation.
by: Barclay, N, et al.
Published: (2006)

The SIRP family of receptors and immune regulation
by: Barclay, A, et al.
Published: (2006)

Surfactant protein D prevents mucin overproduction in airway goblet cells via SIRPα
by: Kentaro Hata, et al.
Published: (2024-01-01)

Preclinical evaluation of the efficacy of an antibody to human SIRPα for cancer immunotherapy in humanized mouse models
by: Yasuyuki Saito, et al.
Published: (2023-12-01)

Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
by: Amy Xiao, et al.
Published: (2022-11-01)

Augmentation of CD47/SIRPα signaling protects cones in genetic models of retinal degeneration
by: Sean K. Wang, et al.
Published: (2021-08-01)

Environmental management activities of NHL teams
by: Laura Márton
Published: (2022-06-01)

Environmental management activities of NHL teams
by: Laura Márton
Published: (2022-06-01)